| Company Name: | YM Biosciences, Inc. | | Ticker Symbol: | YMI | | | WWW Address: | www.ymbiosciences.com | | CEO: | David G.P. Allan | | No. of Employees: | 24 | | Common Issue Type: | CS | | Business Description: | A biopharmaceutical company, which is engaged in the development of products for the treatment of patients with cancer.
|
| | | Industry Information: | DRUGS - Drug Manufacturers - Other [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 1.21 |  0.01 | 1.21 | 1.22 | 1.18 | 1.37 | 1.25 | 28548 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 74.5 | 58.2 | 2.09 | -0.20 | 0.00 | 0.0 | 0.0 | 2.24 - 0.20 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 1.28 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 74.5 | mil |
| Latest Shares Outstanding | 58.2 | mil |
| Earnings pS (EPS) | -0.20 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 163,000 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 0.0 | mil |
| Float as % of Shares Outstanding | 0.0 | % |
| Foreign Sales | 0 | mil |
| Domestic Sales | 0 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 106.50 | % |
| Research & Devlopment (R&D) as % of Revenue | 312.00 | % |
| Gross Profit Margin | 0.0 | % |
| EBITDA Margin | 0.0 | % |
| Pre-Tax Profit Margin | 0.0 | % |
| Assets Turnover | 0.1 | % |
| Return on Assets (ROA) | -28.4 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | -32.9 | % |
| Current Ratio | 12.4 | |
| Leverage Ratio (Assets/Equity) | 1.2 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.00 | |
| LT Debt/Total Capital | 0.0 | % |
| Working Capital pS | 0.58 | $ |
| Cash pS | 0.62 | $ |
| Book-Value pS | 0.59 | $ |
| Tangible Book-Value pS | 0.54 | $ |
| Cash Flow pS | -0.18 | $ |
| Free Cash Flow pS | -0.24 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 2.17 | |
| Price/Tangible Book Ratio | 2.37 | |
| Price/Cash Flow | -7.1 | |
| Price/Free Cash Flow | -5.3 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | -1.5 | 96 | 5,101 | 7,070 |
| 4 Weeks | 1.65 | 1.03 | 1.42 | -9.9 | 90 | 4,163 | 66,610 |
| 13 Weeks | 2.24 | 0.80 | 0.87 | 47.1 | 135 | 6,888 | 413,265 |
| 26 Weeks | 2.24 | 0.43 | 0.44 | 190.9 | 235 | 5,124 | 630,242 |
| 52 Weeks | 2.24 | 0.20 | 0.35 | 265.7 | 292 | 3,123 | 771,391 |
| YTD | 2.24 | 0.20 | - | 245.9 | 286 | 3,397 | 733,833 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 1.30 | 1.26 | 1.45 | 0.89 | 0.74 | 2.09 | 2.08 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 0.00 | 0.0 | 51.25 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 0.00 | NA | 0.00 |
| R&D | 25.19 | NA | -16.04 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 0.0 | 0.0 | -18.1 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 0.0 | 0.0 | 0.0 |
| EPS $ | 0.00 | 0.00 | 0.07 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 85.74 |
| Current Ratio | 12.4 |
| Quick Ratio (Acid Test) | 12.3 |
| Liquidity Ratio (Cash) | 12.13 |
| Receivables Turnover | 8.9 |
| Average Collection Period | 40 |
| Working Capital/Equity | 99.5 |
| Working Capital pS | 0.58 |
| Cash-Flow pS | -0.18 |
| Free Cash-Flow pS | -0.24 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 7.95 |
| Financial Leverage Ratio (Assets/Equity) | 1.2 |
| Debt Ratio | 13.8 |
| Total Debt/Equity (Gearing Ratio) | 0.00 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | 7.3 |
| LT Debt/Total Liabilities | 0.0 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 0.00 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 0.80 |
| Tobin's Q Ratio | 1.88 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -3.82 |
| Enterprise Value (EV)/Free Cash Flow | -3.13 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 2.37 |
| Price/Book Ratio - LTM | 2.17 |
| Price/Cash Flow Ratio | -7.1 |
| Price/Free Cash Flow Ratio - LTM | -5.3 |
| Price/Sales Ratio | 18.29 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | 0 |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.00 |
| Current Liabilities pS | 0.05 |
| Tangible Book Value pS - LTM | 0.54 |
| Book Value pS - LTM | 0.59 |
| Capital Invested pS | 0.59 |
| Cash pS - LTM | 0.62 |
| Cash Flow pS - LTM | -0.18 |
| Free Cash Flow pS - LTM | -0.24 |
| Earnings pS (EPS) | -0.20 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -285.15 |
| Free Cash Flow Margin 5YEAR AVG | -173.86 |
| Net Profit Margin | 0.0 |
| Net Profit Margin - 5YEAR AVRG. | 0.0 |
| Equity Productivity | 0.14 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 0.14 |
| Return on Capital Invested (ROCI) | -32.9 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -35.5 |
| Assets Productivity | 0.10 |
| Return on Assets (ROA) | -28.4 |
| Return on Assets (ROA) - 5YEAR AVRG. | -30.7 |
| Gross Profit Margin | 0.0 |
| Gross Profit Margin - 5YEAR AVRG. | 0.0 |
| EBITDA Margin - LTM | 0.0 |
| EBIT Margin - LTM | 0.0 |
| Pre-Tax Profit Margin | 0.0 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 0.0 |
| Effective Tax Rate | -0.0 |
| Effective Tax Rate - 5YEAR AVRG. | -1.1 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 45 |
| Revenue per Employee | 163,000 |
| Net Income per Employee | -468,917 |
| Average Collection Period | 45 |
| Receivables Turnover | 8.9 |
| Day's Inventory Turnover Ratio | 0 |
| Inventory Turnover | 0.0 |
| Inventory/Sales | 0.0 |
| Accounts Payble/Sales | 7.67 |
| Assets/Revenue | 10.00 |
| Net Working Capital Turnover | 0.14 |
| Fixed Assets Turnover | 1.81 |
| Total Assets Turnover | 0.1 |
| Revenue per $ Cash | 0.11 |
| Revenue per $ Plant | 47.13 |
| Revenue per $ Common Equity | 0.11 |
| Revenue per $ Capital Invested | 0.11 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 106.5 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 205.3 |
| Research & Devlopment (R&D) as % of Revenue | 312.0 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 312.0 |
|
|  
|
| |
 |  |